Literature DB >> 7591958

Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism.

M Ohashi1, E Sugikawa, N Nakanishi.   

Abstract

Abnormality of p53, a tumor suppressor gene, is considered to be a potential cause of malignancy. We found that ellipticine and 9-hydroxyellipticine (9HE), antitumor alkaloids, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 microM. 9HE suppressed cdk2 kinase activity concentration-dependently from 1 to 100 microM. By contrast, the inhibition of p53 protein phosphorylation by elliptinium and elliprabin (N2 substituted derivatives of 9HE) was very weak. A good correlation was observed between p53 phosphorylation inhibition and cytotoxic activity of these agents in terms of concentration-response relationships, suggesting that inhibition of p53 protein phosphorylation via kinase inhibition may be involved in the anticancer mechanism of these agents. In addition, this study demonstrated that brief exposure to 9HE caused apoptosis of cancer cells. It is suggested that accumulation of dephosphorylated mutant p53 may induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591958      PMCID: PMC5920929          DOI: 10.1111/j.1349-7006.1995.tb03091.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  50 in total

1.  Functional implications of the growth-suppressor oncoprotein p53.

Authors:  M Montenarh
Journal:  Int J Oncol       Date:  1992-06       Impact factor: 5.650

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

4.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.

Authors:  E Multon; J F Riou; D LeFevre; J C Ahomadegbe; G Riou
Journal:  Biochem Pharmacol       Date:  1989-07-01       Impact factor: 5.858

6.  Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.

Authors:  W H Westra; G J Offerhaus; S N Goodman; R J Slebos; M Polak; I O Baas; S Rodenhuis; R H Hruban
Journal:  Am J Surg Pathol       Date:  1993-03       Impact factor: 6.394

7.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

8.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

9.  p53 is associated with p34cdc2 in transformed cells.

Authors:  J Milner; A Cook; J Mason
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

10.  Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes.

Authors:  Y Kakeji; D Korenaga; S Tsujitani; H Baba; H Anai; Y Maehara; K Sugimachi
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  10 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

2.  Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.

Authors:  William J Andrews; Tatiana Panova; Christophe Normand; Olivier Gadal; Irina G Tikhonova; Konstantin I Panov
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

3.  Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.

Authors:  Fei Wang; Jianfeng Liu; Delira Robbins; Kerri Morris; Amos Sit; Yong-Yu Liu; Yunfeng Zhao
Journal:  Apoptosis       Date:  2011-03       Impact factor: 4.677

4.  A novel high-through-put assay for screening of pro-apoptotic drugs.

Authors:  Maria Hägg; Kenneth Bivén; Takayuki Ueno; Lars Rydlander; Peter Björklund; Klas G Wiman; Maria Shoshan; Stig Linder
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study.

Authors:  Santhi Latha Pandrangi; Rajasekhar Chikati; Pradeep Singh Chauhan; Chitta Suresh Kumar; Anropa Banarji; Sunita Saxena
Journal:  Tumour Biol       Date:  2013-08-28

6.  Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.

Authors:  E G Russell; E C O'Sullivan; C M Miller; J Stanicka; F O McCarthy; T G Cotter
Journal:  Invest New Drugs       Date:  2014-08-10       Impact factor: 3.850

7.  Ellipticine cytotoxicity to cancer cell lines - a comparative study.

Authors:  Marie Stiborová; Jitka Poljaková; Eva Martínková; Lucie Bořek-Dohalská; Tomáš Eckschlager; Rene Kizek; Eva Frei
Journal:  Interdiscip Toxicol       Date:  2011-06

Review 8.  The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.

Authors:  Marie Stiborová; Věra Černá; Michaela Moserová; Iveta Mrízová; Volker M Arlt; Eva Frei
Journal:  Int J Mol Sci       Date:  2014-12-25       Impact factor: 5.923

9.  Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells.

Authors:  Maria Zeniou; Marie Fève; Samir Mameri; Jihu Dong; Christophe Salomé; Wanyin Chen; Elias A El-Habr; Fanny Bousson; Mohamadou Sy; Julie Obszynski; Alexandre Boh; Pascal Villa; Suzana Assad Kahn; Bruno Didier; Dominique Bagnard; Marie-Pierre Junier; Hervé Chneiweiss; Jacques Haiech; Marcel Hibert; Marie-Claude Kilhoffer
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

10.  Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells.

Authors:  H Nakata; Y Kikuchi; T Tode; J Hirata; T Kita; K Ishii; K Kudoh; I Nagata; N Shinomiya
Journal:  Jpn J Cancer Res       Date:  1998-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.